Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States

References

• Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41
   PubMed Web of Science ®Google Scholar
• Goldenberg D, Mayskiy M, Mossey C, et al. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, et al. and the Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73
   PubMed Web of Science ®Google Scholar
• Lawson K. Emerging pharmacological therapies for fibromyalgia. Curr Opin Investig Drugs 2006;7:631-6
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzhcharles, MA, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res 2010;62:600-10
   PubMed Web of Science ®Google Scholar
• Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract 2008;8:177-89
   PubMedGoogle Scholar
• Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008;62:115-26
   PubMed Web of Science ®Google Scholar
• Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28
   PubMed Web of Science ®Google Scholar
• Macfarlane GJ. Fibromyalgia and chronic widespread pain. In: Crombie IK, ed. Epidemiology of Pain. Seattle: IASP Press, 1999:113-23
   Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med 1994; 23:129-38
   PubMedGoogle Scholar
• Tan G, Jensen MP, Thornby JI, et al. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5:133-7
   PubMed Web of Science ®Google Scholar
• Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire (FIQ): development and validation. J Rheumatol 1991;18:728-33
   PubMed Web of Science ®Google Scholar
• Dunkl PR, Taylor AG, McConnell GG, et al. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000;27:2683-91
   PubMed Web of Science ®Google Scholar
• Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome – a systematic review. Eur J Pain 2010;14:5-10
   PubMed Web of Science ®Google Scholar
• Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview, IL: American Pain Society, 2005
   Google Scholar
• O’Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000;15:659-66
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol 2005;32:2270-7
   PubMed Web of Science ®Google Scholar
• Choy E, Richards S, Bowrin K, et al. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin 2010;26:965-75
   PubMed Web of Science ®Google Scholar
• Kleinman N, Harnett J, Melkonian A, et al. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med 2009;51:1384-93
   PubMed Web of Science ®Google Scholar
• Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum 2008;58:895-902
   PubMed Web of Science ®Google Scholar
• Annemans L, Le Lay K, Taïeb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics 2009;27:547-59
   PubMed Web of Science ®Google Scholar
• White LA, Robinson RL, Yu AP, et al. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain 2009;10:976-83
   PubMed Web of Science ®Google Scholar
• Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother 2006;7:1027-39
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009;11:R54
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. No. 1618, 2008. Available at: www.nice.org.uk. [Last accessed 8 July 2008]
   Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
   PubMed Web of Science ®Google Scholar
• Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2009;1:91-102
   Google Scholar
• Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
   PubMed Web of Science ®Google Scholar
• Wells GA, Sultan SA, Chen L, et al. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa, Ontario: Canadian Agency for Drugs and Technologies in Health, 2009
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472
   PubMed Web of Science ®Google Scholar
• Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409
   Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
   PubMed Web of Science ®Google Scholar
• Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45
   PubMed Web of Science ®Google Scholar
• Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52:2495-505
   PubMed Web of Science ®Google Scholar
• Bennett RM, Gatter RA, Campbell, SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis: a double blind controlled study. Arthritis Rheum 1988;31:1535-42
   PubMed Web of Science ®Google Scholar
• Carette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986;29:655-9
   PubMed Web of Science ®Google Scholar
• Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994;37:32-40
   PubMed Web of Science ®Google Scholar
• Carette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995;38:1211-17
   PubMed Web of Science ®Google Scholar
• Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol 2001;19:697-702
   PubMed Web of Science ®Google Scholar
• Quimby LG, Gratwick GM, Whitney CD, et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl 1989;19:140-3
   PubMedGoogle Scholar
• Scudds RA, McCain GA, Rollman GB, et al. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl 1989;19:98-103
   PubMedGoogle Scholar
• Choy EH, Mease PJ, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin Rheumatol 2009;28:1035-44
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• RedBookTMor Windows®, Version 61127, Volume 53. Montvale, NJ: Thomson PDR, Release date: July 2009
   Google Scholar
• RBRVS. The Essential Resource Based Relative Value Scale (RBRVS): a comprehensive listing of RBRVS values for CPT and HCPCS codes. Salt Lake City, UT: Ingenix, 2009
   Google Scholar
• Penrod JR, Bernatsky S, Adam V, et al. Health services costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31:1391-8
   PubMed Web of Science ®Google Scholar
• White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: Medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
   PubMed Web of Science ®Google Scholar
• AMCP Format for Formulary Submissions, Version 3.0 www.amcp.org/data/jmcp/1007_121%2019%2009(3).pdf
   Google Scholar